- Academic Editor
Background: Multiple sclerosis (MS) is an autoimmune disease for which
bone marrow mesenchymal stem cells (BM-MSCs) have become one of the most
promising tools for treatment. Cuprizone(CPZ) induces demyelination in the
central nervous system and its use has established a demyelination sheath animal
model which is particularly suitable for studying the effects of BM-MSCs on
the remyelination and mood improvement of a demyelinating model mice.
Methods: 70 C57BL/6 male mice were selected and divided into 4 groups:
the normal control (n = 20), chronic demyelination (n = 20),
myelin repair (n = 15) and cell-treated groups (n = 15). Mice
in the normal control group were given a normal diet; the chronic demyelination
group mice were given a 0.2% CPZ mixed diet for 14 weeks, mice in the myelin
repair and cell-treated groups mice were given a 0.2% CPZ diet for 12 weeks and
normal diet for 2 weeks, while the cell-treated group mice were injected with
BM-MSCs from the 13th week. The cuprizone-induced demyelination model was
successfully established and BM-MSCs extracted, behavioural changes of the mice
were detected by open field test, elevated plus maze test and tail suspension
test, demyelination and repair of the corpus callosum and astrocyte changes were
observed by immunofluorescence and electron microscopy and the concentrations of
monoamine neurotransmitters and their metabolites detected by enzyme-linked
immunosorbent assay (ELISA) and high performance liquid
chromatography-electrochemistry (HPLC-ECD). Results: Results suggest
BM-MSCs were successfully extracted and cultured, and migrated to the
demyelinating area of brain tissue after cell transplantation. Compared with the
normal control group, the mice in the chronic demyelination group showed obvious
anxiety and depression behaviours (p
The demyelination model is successfully induced, and BM-MSCs can promote myelin repair.
The loss of myelin sheath and the repair process may be related to anxiety or depressive behaviour.
The activated astrocytes may promote the loss of myelin sheath and inhibit the regeneration of myelin sheath.
BM-MSCs can partially ameliorate the disorder of monoamine neurotransmitters in demyelination model mice.